AbbVie Inc. (ABBV)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Richard A. Gonzalez | Chairman & CEO | 7.19M | -- | 1954 |
Mr. Robert A. Michael | President & COO | 4.62M | -- | 1970 |
Mr. Scott T. Reents | Executive VP & CFO | 3.13M | -- | 1968 |
Dr. Azita Saleki-Gerhardt Ph.D. | Executive VP & COO | 3.51M | 5.25M | 1963 |
Mr. Jeffrey Ryan Stewart | Executive VP & Chief Commercial Officer | 4.32M | 2.13M | 1969 |
Dr. Thomas J. Hudson M.D. | Senior VP & Chief Scientific Officer of Global Research | -- | -- | 1962 |
Ms. Elizabeth Shea | Senior Vice President of Investor Relations | -- | -- | -- |
Mr. Perry C. Siatis | Executive VP, General Counsel & Secretary | -- | -- | 1975 |
Mr. Sanjay Narayan | Senior VP, Chief Ethics, Compliance Officer & Allergan Aesthetic Legal | -- | -- | -- |
Mr. Timothy J. Richmond | Executive VP & Chief Human Resources Officer | 1.12M | -- | 1966 |
AbbVie Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - General
- Full Time Employees:
- 50,000
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Corporate Governance
Recent Events
- Apr 12, 2024Ex-Dividend Date
- Apr 03, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 18, 2024DEF 14A: Proxy StatementsSee Full Filing
- Mar 04, 2024PRE 14A: Proxy StatementsSee Full Filing
- Feb 26, 20248-K: Corporate Changes & Voting MattersSee Full Filing
Upcoming Events
May 15, 2024
Dividend Date